Surprised By Doximity's 54% Slide? What Investors Overlooked

If you had circled Doximity as a pure-play bet on AI tools for doctors and digital pharma ads a year ago, the outcome would have stung. Holding Doximity over the past year would have meant a 54.2% loss, including dividends. That result now sits alongside slowing growth guidance, legal probes, and margin pressure. The real puzzle is which early clues on regulation, competition, and dependence on pharma marketing were already on the table before that slide began.

This theme extends beyond Doximity. See which of 33 healthcare AI stocks may still merit a closer look.

The Argument Doximity Investors Were Really Having

The shares cost US$67.33 at the start of the period, and anyone looking at Doximity had to decide which story felt more realistic. One camp saw a specialist network ready to ride digital healthcare and AI tools deeper into doctors’ daily routines. Another group worried that the same themes, especially data rules and platform saturation, could cap the upside and drag on profitability.

The bullish view pinned a Fair Value of US$80 on Doximity, a price that only worked if its assumptions played out. That story leaned on AI tools and workflow modules, with point-of-care and formulary products growing very quickly and already making up 20% of pharma sales, as a way to widen the platform’s opportunity set.

The bearish side anchored on a Fair Value of US$50.42, framed as what the business might be worth if risks bit harder. That case focused on tighter digital privacy regulation raising compliance costs and limiting how effectively Doximity could monetise data-driven advertising and workflow products.

What The Results Changed For The Doximity Argument

Doximity’s reported Q1 2027 figures gave both sides new data to chew on. Revenue reached US$156.6 million compared with US$145.9 million a year earlier, which leaned toward the bullish view that AI tools could widen the platform’s opportunity. Net income fell to US$24.3 million from US$53.3 million, and net margin dropped from 36.5% to 15.5%. The evidence cut both ways.

The lesson for readers is simple. When a story leans on higher quality revenue and better profitability, check whether net income and net margin actually move in the same direction as sales before trusting the narrative.

What Doximity’s Lower Price Now Asks You To Believe

Doximity trades at US$30.97 today, well below where it sat a year ago. The selected Narrative places its Fair Value above that level and highlights AI tools, workflow products, and buybacks as the key supports for that view.

For that higher figure to be reached, a buyer today would be assuming that rising clinician use of Doximity’s AI products converts into sturdier, higher margin enterprise and pharma spend.

"The main thing that has to go right is that Doximity converts rising clinician usage of its AI and workflow products, together with a more stable pharma budget backdrop and strong SMB pharma bookings, into durable enterprise and pharma spending that outweighs higher AI compute and stock-based compensation costs."

The price and this Narrative do not agree. → Uncover what this Narrative says Doximity is actually worth

Looking Beyond Doximity’s Screen

Doximity keeps your focus on doctors’ workflows and digital outreach. That is only one slice of a much bigger healthcare puzzle.

Those same clinicians also manage benefit designs, pharmacy coverage and complex care programs. A different operator is quietly handling that infrastructure behind the scenes.

Another large player is testing value-based care, home health pilots and rural house calls. The goal is tighter coordination, fewer unnecessary hospital stays and steadier plan performance.

It is also rolling out AI tools across claims, call centers and clinical documentation. If that effort reshapes its costs, the ripple effects could extend well beyond Doximity.

That argument has a Narrative and a number behind it. → See the company one Narrative values 20% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com